Piper Sandler started coverage on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $26.00 price target on the stock. Separately, Oppenheimer reaffirmed an outperform rating and set a $16.00 price target (down previously from $17.00) […]

Related Keywords

Amit Munshi , Piper Sandler , Zura Bio , Securities Exchange Commission , Raymond James Associates , Forefront Analytics , York Mellon Corp , Eisler Capital , Free Report , Marketbeat Ratings , Director Amit Munshi , Exchange Commission , New York Mellon Corp , Get Free Report , Bio Limited , Zura Bio Daily , Nasdaq Zura , Kazura , Medical , Initiated Coverage ,